A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study(dagger)

J. G. Aerts, H. Codrington, N. A. G. Lankheet, S. Burgers, B. Biesma, A. -M. C. Dingemans, A. D. Vincent, O. Dalesio, H. J. M. Groen, E. F. Smit

Research output: Contribution to journalArticleAcademicpeer-review

31 Citations (Scopus)
Original languageEnglish
Pages (from-to)2860-2865
JournalAnnals of Oncology
Volume24
Issue number11
DOIs
Publication statusPublished - Nov 2013

Keywords

  • NSCLC
  • second line
  • intercalated
  • erlotinib

Cite this

Aerts, J. G., Codrington, H., Lankheet, N. A. G., Burgers, S., Biesma, B., Dingemans, A. -M. C., Vincent, A. D., Dalesio, O., Groen, H. J. M., & Smit, E. F. (2013). A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study(dagger). Annals of Oncology, 24(11), 2860-2865. https://doi.org/10.1093/annonc/mdt341